

- ...
- ...

,

() () , () () , () 27,5 , () -0,75 1 () () [7, 8, 9]. () -1, -8, 90 [7, 10]. () () KRKA) 1 () -10 () -100 () -50 [4, 5, 6]. (" ") . [4].

" (5), ()
 10 " " 2
 [1, 4, 5, 6]. 1 2
 " " " 6 " -
 " " " 2 " .
 " " " 3 : -
 " -3" (2005),
 " " ")
 : " -3" (2005)
 2 / , : 4 ()
 500 3 500 / 4 120 / , -
 16). 1 (=16) 2 (=
 97 1 (=15) 2 (=16).
 200 2 1000 2 500
 (35,3±1,4) 20 50 ,
 (8,2±2,2) 1 23
 () ()
 () .
 [5,11].
 2 1 3 / 3 " "
 : — 47 ,
 — 50 ,
 () — () .
 2,5

(±)

	(=15)			
		(=47)	(=50)	
, /	3,15±0,21	7,84±0,36*	7,58±0,35*	>0,05
, /	6,27±0,18	15,93±0,45*	16,31±0,25*	>0,05

: 1. — ; 2.
* — <0,05.

, — 2,4 (<0,05). () ()
— 2.

2,7 : 2,6 , — 2, , 1,7 ,
(<0,05). 1,5 (<0,05)

2

(±)

	(=15)			
		(=47)	(=50)	
, /	369,3±14,3	221,3±9,0*	218,7±8,5*	>0,05
, /	29,1±1,4	19,4±0,6*	20,1±0,5*	>0,05

: — ; —
* — <0,05.

3

(±)

	(=15)			
		(=47)	(=50)	
, /	3,15±0,21	7,84±0,36	3,56±0,25*	>0,05
, /	6,27±0,18	15,93±0,45	6,93±0,37*	<0,05

: 1. — ; 2. * — <0,05

(±)

	(=15)			
		(=50)	(=50)	
, /	3,15±0,21	7,58±0,35	5,05±0,23*	<0,05
, /	6,27±0,18	16,31±0,25	10,19±0,28*	<0,05

: 1. — ; 2. * — <0,05

5, ,
 — 2,3^{2,2} ,
 (<0,05 3, ,). 1,6 ,
 (>0,05). 1,5
 (>0,05),
 — (. 4) (>0,05),
 — 1,6^{1,5} (<0,05).
 4, , (. 6).
 (<0,05). — 1,1^{1,2} (<0,05)

(±)

	(=15)			
		(=47)	(=47)	
, /	369,3±14,3	221,3±9,0	354,10±15,1*	>0,05
, /	29,1±1,4	19,4±0,6	28,14±0,5*	>0,05

: 1. — ; 2. * — <0,05

(±)

	(=15)			
		(=50)	(=50)	
, /	369,3±14,3	218,7±8,5	262,4±9,1*	<0,05
, /	29,1±1,4	20,1±0,5	22,9±0,4*	<0,05

: — ; * — <0,05

(<0,05).

3.

1.

2.

1. ... / ... - 2003. - . 35. - 3. - 92-99.

2. ... / ... - 2005. - 1. - . 79-82.

3. ... // ... - 2002. - 9. - 64-73.

4. ... // ... - 2008. - 10. - 63-64.

5. ... // ... - 2008. - 9. - 37-41.

6. ... // ... - 2006. - 6. - . 113-129.

7. ... /

B. ., ... // ... - 2000. - 5. - . 38-44.

8. ... / ... - 2000. - 1. - . 26-28.

9. ... // ... - 2002. - . 80. - 9. - C. 35-37.

10. ... // ... - 2004. - 1. - . 57-60.

11. Figueiredo . Pathogenesis of *Helicobacter pylori* Infection /Figueiredo C., Machado J., Yamaoka Y. //*Helicobacter*. - 2005. - Vol. 10 Suppl 1. - . 14-20.

12. Kim H. Oxidative stress in *Helicobacter pylori*-induced gastric cell injury / Kim H. // *Inflammopharmacol.* - 2005. - Vol. 13(1). - . 63-74.

13. Li C. Q. Increased oxidative and nitrate stress in human stomach associated with *cagA+* *Helicobacter pylori* infection and inflammation / Li C.Q, Pignatelli B., Ohshima H. // *Dig Dis Sci*. - 2001. - Vol. 46(4). - . 836-844.

11.01.2010

, H.pylori,

" "

, H.pylori,

" "

N. Kharchenko, S.Vlasyuk

BASED SELECTION OF "LIPOFLAVON" AND "TRIOVIT" IN COMPLEX PATHOGENETIC THERAPY OF PEPTIC DUODENAL ULCUS WITH COMPLICATIONS AND RELAPSES

Key words: peptic duodenal ulcer, complications, H.pylori, oxidants, antioxidants, lipid peroxidation

The application of antioxydant medicines "Lipoflavon" and "Triovit" in patients with complicated peptic duodenal ulcer on the background traditional are based in this article.

615.27.015.11

-
-

7]. 40-

[3, () [1, 5, 6].

[4].

1, 2); ()

, 1, 2); ()